1 min read
Add as a preferred source on Google

Larimar Therapeutics Estimates $128.7 Million in Cash at Quarter-End

The preliminary, unaudited estimate covers cash, equivalents and marketable securities as of Sept. 30, 2026. Larimar projects its cash runway into late Q2 2027.

A transparent cash box sits at the end of an empty laboratory shelf / TokenPost.ai
A transparent cash box sits at the end of an empty laboratory shelf / TokenPost.ai

Larimar Therapeutics, Inc. estimated it had $128.7 million in cash, cash equivalents and marketable securities at the end of September, with a projected cash runway into late Q2 2027.

The figure was preliminary and unaudited as of Sept. 30, 2026, and could change after the quarter-end close.

Larimar’s cash runway projection extends into late Q2 2027.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…